Provided by Tiger Trade Technology Pte. Ltd.

Oppenheimer

85.40
+1.902.28%
Post-market: 85.400.00000.00%16:10 EDT
Volume:35.06K
Turnover:3.00M
Market Cap:914.40M
PE:6.55
High:86.47
Open:85.16
Low:83.87
Close:83.50
52wk High:94.10
52wk Low:49.26
Shares:10.71M
Float Shares:5.93M
Volume Ratio:0.81
T/O Rate:0.59%
Dividend:0.72
Dividend Rate:0.84%
EPS(TTM):13.04
EPS(LYR):13.04
ROE:16.02%
ROA:4.16%
PB:0.93
PE(LYR):6.55

Loading ...

Oppenheimer Adjusts MongoDB Price Target to $375 From $425, Maintains Outperform Rating

MT Newswires Live
·
Mar 03

Oppenheimer Adjusts Price Target on XPO to $228 From $198, Maintains Outperform Rating

MT Newswires Live
·
Mar 03

MongoDB Is Maintained at Outperform by Oppenheimer

Dow Jones
·
Mar 03

Oppenheimer Adjusts Price Target on BlackRock TCP Capital to $6 From $7, Maintains Perform Rating

MT Newswires Live
·
Mar 03

Once Upon a Farm initiated with an Outperform at Oppenheimer

TIPRANKS
·
Mar 03

Evolent Health Is Maintained at Outperform by Oppenheimer

Dow Jones
·
Mar 02

Oppenheimer Adjusts SentinelOne Price Target to $20 From $24, Maintains Outperform Rating

MT Newswires Live
·
Mar 02

Oppenheimer Adjusts Netskope Price Target to $23 From $28, Maintains Outperform Rating

MT Newswires Live
·
Mar 02

Oppenheimer Holdings Inc. Announces Annual Stockholder Meeting

Reuters
·
Mar 02

Oppenheimer Sticks to Its Buy Rating for Denali Therapeutics (DNLI)

TIPRANKS
·
Mar 02

Oppenheimer Sticks to Their Buy Rating for Netskope, Inc. (NTSK)

TIPRANKS
·
Mar 02

Oppenheimer Remains a Hold on PubMatic (PUBM)

TIPRANKS
·
Feb 28

Sezzle Inc. (SEZL) Gets a Buy from Oppenheimer

TIPRANKS
·
Feb 28

Bentley Systems Is Maintained at Outperform by Oppenheimer

Dow Jones
·
Feb 27

Oppenheimer Trims Price Target on Palmer Square Capital to $13 From $14, Maintains Perform Rating

MT Newswires Live
·
Feb 27

Oppenheimer Adjusts Price Target on Zscaler to $280 From $345, Maintains Outperform Rating

MT Newswires Live
·
Feb 27

Oppenheimer Adjusts Price Target on Sweetgreen to $9 From $10, Maintains Outperform Rating

MT Newswires Live
·
Feb 27

Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $277 From $275, Maintains Outperform Rating

MT Newswires Live
·
Feb 27

Oppenheimer Adjusts Price Target on Chemed to $500 From $580, Maintains Outperform Rating

MT Newswires Live
·
Feb 27

Oppenheimer Adjusts Price Target on Block to $89 From $85, Maintains Outperform Rating

MT Newswires Live
·
Feb 27